ATE554172T1 - Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung - Google Patents

Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung

Info

Publication number
ATE554172T1
ATE554172T1 AT00938875T AT00938875T ATE554172T1 AT E554172 T1 ATE554172 T1 AT E554172T1 AT 00938875 T AT00938875 T AT 00938875T AT 00938875 T AT00938875 T AT 00938875T AT E554172 T1 ATE554172 T1 AT E554172T1
Authority
AT
Austria
Prior art keywords
derivatives
induce
ctl
retro
hiv
Prior art date
Application number
AT00938875T
Other languages
English (en)
Inventor
Jeannine Choppin
Villada Isabelle Bourgault
Jean-Gerard Guillet
Francine Connan
Estelle Ferries
Original Assignee
Assist Publ Hopitaux De Paris
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris, Inst Nat Sante Rech Med filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of ATE554172T1 publication Critical patent/ATE554172T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00938875T 1999-06-03 2000-05-31 Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung ATE554172T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907012A FR2794370B1 (fr) 1999-06-03 1999-06-03 Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
PCT/FR2000/001513 WO2000075336A2 (fr) 1999-06-03 2000-05-31 Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination

Publications (1)

Publication Number Publication Date
ATE554172T1 true ATE554172T1 (de) 2012-05-15

Family

ID=9546327

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00938875T ATE554172T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung
AT00936995T ATE448244T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00936995T ATE448244T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung

Country Status (9)

Country Link
US (3) US6783763B1 (de)
EP (3) EP1181314B8 (de)
AT (2) ATE554172T1 (de)
AU (2) AU5411000A (de)
CA (2) CA2375602A1 (de)
DE (1) DE60043299D1 (de)
ES (2) ES2386803T3 (de)
FR (1) FR2794370B1 (de)
WO (2) WO2000075181A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP2278024A1 (de) * 2000-04-28 2011-01-26 Mannkind Corporation Antigener peptide von NY-ESO-1 und deren verwendung als impfstoffe gegen Tumor
EP2363406B1 (de) * 2000-12-08 2019-02-27 Academisch Ziekenhuis Leiden Lange Peptide aus 22-45 Aminosäureresten, die die antigenspezifischen Immunreaktionen induzieren und/oder verbessern
CA2431500C (en) * 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP1213299A1 (de) * 2000-12-08 2002-06-12 Leids Universitair Medisch Centrum Immunogene epitopen des menschlichen Papillom-Virus und deren Anwendung
FR2820425B1 (fr) * 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
DK1478659T3 (da) * 2001-07-13 2009-01-05 Cms Peptides Patent Holding Co Biologisk aktive peptider
CN1210295C (zh) 2001-07-13 2005-07-13 一泰医药研究（深圳）有限公司 序列号24的生物活性肽
EP1806410A3 (de) * 2001-08-23 2007-10-24 Merck & Co., Inc. Floureszente, multiplexe HPV-PCR-Assays unter Verwendung multipler Fluorophore
CA2469738A1 (en) 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
AU2003271215A1 (en) * 2002-10-17 2004-05-04 Bioleaders Corporation Vector for anti-hpv vaccine and transformed microorganism by the vector
EP1699479A1 (de) * 2003-12-24 2006-09-13 Leiden University Medical Center Synthetisches protein als tumorspezifischer impfstoff
CA2552508A1 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CN1950483A (zh) * 2004-04-28 2007-04-18 上游重油有限公司 固定床加氢处理法和系统，以及用来升级已有固定床系统的方法
US10941353B2 (en) 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
EP2811006A1 (de) 2004-04-28 2014-12-10 Headwaters Heavy Oil, LLC Verfahren und Systeme zur Fließbetthydrierung sowie Systeme und Verfahren zur Aufrüstung eines bestehenden Fließbettsystems
DE602005022759D1 (de) 2004-12-08 2010-09-16 Gen Probe Inc Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US20070037180A1 (en) * 2005-02-10 2007-02-15 Olle Nilsson Site-specific immunization in order to establish antibodies with specificity for the E7 oncoprotein of high-risk HPV's
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
WO2008014521A2 (en) * 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2152729B1 (de) 2007-05-31 2013-03-20 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Hpv-epitope, auf die gebärmutterhalsmalignitäten infiltrierende t-zellen zielen, zur verwendung in impfstoffen
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
JP5267969B2 (ja) * 2007-12-04 2013-08-21 学校法人慶應義塾 癌ワクチン
EP2276495B1 (de) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulierung einer immunantwort durch enantiomere von kationischen lipiden
WO2010033617A2 (en) * 2008-09-16 2010-03-25 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
KR101471043B1 (ko) 2009-01-08 2014-12-09 주식회사 바이오리더스 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균
EP2445927B1 (de) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidierte tumorassoziierte antigene und immuntherapiezusammensetzungen
US20120225090A1 (en) * 2009-08-03 2012-09-06 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
EP2678442B1 (de) 2011-02-24 2019-01-16 QIAGEN Gaithersburg, Inc. Materialien und verfahren für den nachweis von hpv-nukleinsäuren
CN104066444A (zh) * 2011-09-12 2014-09-24 Pds生物科技公司 微粒疫苗制剂
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
EP4091630A1 (de) 2012-09-21 2022-11-23 PDS Biotechnology Corporation Impfstoffe mit r-dotap
CN103342738B (zh) 2013-07-24 2015-02-18 广州恒上医药技术有限公司 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽
WO2016005789A1 (en) * 2014-07-07 2016-01-14 Institut Pasteur Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus- associated cancer stages
EP3421046A1 (de) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutische hpv16-impfstoffe
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
EP3374496A4 (de) 2015-11-13 2019-07-10 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
BR112018072372A2 (pt) 2016-05-02 2019-02-19 Janssen Vaccines & Prevention B.V. combinações de vacina terapêutica contra o hpv
EP3463577A4 (de) * 2016-06-03 2019-12-04 Etubics Corporation Zusammensetzungen und verfahren zur behandlung von mit humanem papillomvirus (hpv) assoziierten erkrankungen
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
MY201964A (en) 2016-06-20 2024-03-27 Isa Pharmaceuticals B V Formulation of a peptide vaccine
CN108164587A (zh) * 2016-12-07 2018-06-15 中国医学科学院肿瘤医院 新的hpv抗原表位
JP7336831B2 (ja) 2017-03-02 2023-09-01 ハイドロカーボン テクノロジー アンド イノベーション、エルエルシー ファウリングが少ない堆積物を伴う改良された沸騰床リアクター
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
CN111868074A (zh) * 2018-01-24 2020-10-30 昆士兰医学研究所理事会 Hpv免疫疗法
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
US12497569B2 (en) 2022-05-26 2025-12-16 Hydrocarbon Technology & Innovation, Llc Method and system for mixing catalyst precursor into heavy oil using a high boiling hydrocarbon diluent
EP4701650A2 (de) 2023-04-26 2026-03-04 Isabella Pharma B.V. Verfahren zur behandlung von krebs durch verabreichung immunogener zusammensetzungen und eines pd-1-inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
FR2641081A1 (de) * 1988-12-23 1990-06-29 Medgenix Group
CA2038581A1 (en) 1990-03-20 1991-09-21 Martin Muller Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DK0523391T3 (da) * 1991-07-13 2003-06-23 Dade Behring Marburg Gmbh Anvendelse af HPV-16 E6 og E7 genafledte peptider til diagnostisk formål
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
AU685521B2 (en) * 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
ES2205209T3 (es) * 1996-04-26 2004-05-01 Rijksuniversiteit Te Leiden Procedimientos de seleccion y de produccion de epitopos peptidicos de linfocitos t y vacunas que contienen los indicados epitopos seleccionados.
AUPO390396A0 (en) * 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques

Also Published As

Publication number Publication date
EP1181314B1 (de) 2009-11-11
US6783763B1 (en) 2004-08-31
CA2375602A1 (fr) 2000-12-14
EP2267132A3 (de) 2011-04-20
FR2794370A1 (fr) 2000-12-08
WO2000075181A1 (fr) 2000-12-14
EP2267132A2 (de) 2010-12-29
WO2000075336A3 (fr) 2001-07-26
ES2509901T3 (es) 2014-10-20
AU5229400A (en) 2000-12-28
US7288258B2 (en) 2007-10-30
EP1181314B8 (de) 2010-02-17
EP1183368B1 (de) 2012-04-18
AU5411000A (en) 2000-12-28
US20080248044A1 (en) 2008-10-09
EP2267132B1 (de) 2014-07-16
FR2794370B1 (fr) 2003-10-17
WO2000075336A2 (fr) 2000-12-14
US20050033025A1 (en) 2005-02-10
EP1183368A2 (de) 2002-03-06
EP1181314A1 (de) 2002-02-27
ATE448244T1 (de) 2009-11-15
ES2386803T3 (es) 2012-08-31
DE60043299D1 (de) 2009-12-24
CA2375627A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
ATE554172T1 (de) Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung
FI932678A7 (fi) Alfaviruksiin perustuvia DNA-ilmentämissysteemejä
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
RU2002111335A (ru) Среда для культивирования клеток без белков и без сыворотки
JPS60115528A (ja) ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
JP4047176B2 (ja) 培地添加剤および動物細胞培養用培地
JP7728755B2 (ja) 細胞を再プログラム化して形質細胞様樹状細胞またはｉ型インターフェロン産生細胞に変換する組成物、その方法および用途
RU2401307C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFK2, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО ПЕПТИДА, ЯВЛЯЮЩЕГОСЯ АНАЛОГОМ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ПЕПТИДА И РЕКОМБИНАНТНЫЙ ПЕПТИД, АНАЛОГ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, ОБЛАДАЮЩИЙ АПОПТОТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РАКОВЫМ КЛЕТКАМ
ES2561483T3 (es) Antígenos mutantes de GAS57 y anticuerpos de GAS57
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ATE169958T1 (de) Herstellung der p1 proteine und impfstoffe gegen gonorrhöe
ATE351904T1 (de) Einem peptid aus antigen muc-1 entsprechende dns zur auslösung einer immunreaktion gegen tumorzellen
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
JPS61225130A (ja) 鶏卵卵白システインの単離方法およびこれを含有するウイルス感染の処置剤
Holtet et al. Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative
CN101041816B (zh) 人工抗原递呈细胞及其制备方法
CN110078793A (zh) 一种具有抗衰老和修复作用的多肽及其用途
BR9713540A (pt) Procedimento para a expressão do gene do vìrus da dengue
NO874704L (no) Minaktivin fremstilt ved rekombinant dna-teknikk.
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
RU2614124C9 (ru) Оптимизированный ген, кодирующий рекомбинантный белок ипфiii
CN101016540B (zh) C-端含有组氨酸标记的hoxb4重组蛋白质的制造方法及用途
Riding et al. A strategy for purification and peptide sequence analysis of bovine ephemeral fever virus structural proteins
Ivey-Hoyle et al. E2F-2, a novel mammalian transcription factor
Dinic et al. C/EBPα and C/EBPβ are persistently associated with the rat liver nuclear matrix throughout development and the acute phase response